PL1670514T3 - Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II - Google Patents

Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II

Info

Publication number
PL1670514T3
PL1670514T3 PL04773539T PL04773539T PL1670514T3 PL 1670514 T3 PL1670514 T3 PL 1670514T3 PL 04773539 T PL04773539 T PL 04773539T PL 04773539 T PL04773539 T PL 04773539T PL 1670514 T3 PL1670514 T3 PL 1670514T3
Authority
PL
Poland
Prior art keywords
inhibitor
topoisomerase
histone deacetylase
antitumor agent
deacetylase inhibitor
Prior art date
Application number
PL04773539T
Other languages
English (en)
Inventor
Yoshinori Naoe
Yuka Sasakawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1670514T3 publication Critical patent/PL1670514T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL04773539T 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II PL1670514T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003334340 2003-09-25
JP2003344315 2003-10-02
EP04773539A EP1670514B1 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
PCT/JP2004/014451 WO2005030239A2 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor

Publications (1)

Publication Number Publication Date
PL1670514T3 true PL1670514T3 (pl) 2010-11-30

Family

ID=34380371

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10163527T PL2263694T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II
PL04773539T PL1670514T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10163527T PL2263694T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II

Country Status (14)

Country Link
US (1) US7314862B2 (pl)
EP (2) EP1670514B1 (pl)
JP (1) JP4779971B2 (pl)
AT (1) ATE471740T1 (pl)
CA (1) CA2540108A1 (pl)
CY (1) CY1114359T1 (pl)
DE (1) DE602004027824D1 (pl)
DK (1) DK2263694T3 (pl)
ES (2) ES2344899T3 (pl)
MX (1) MXPA06003222A (pl)
PL (2) PL2263694T3 (pl)
PT (1) PT2263694E (pl)
SI (1) SI2263694T1 (pl)
WO (1) WO2005030239A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1426054T3 (da) * 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2519320A1 (en) * 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US7314862B2 (en) 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1904452A2 (en) * 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007040522A1 (en) * 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
JP2009519224A (ja) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008013589A2 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101674820B (zh) * 2006-12-26 2013-09-25 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法
MX2009006969A (es) * 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Purificacion de romidepsina.
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
US8034768B2 (en) * 2007-06-22 2011-10-11 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
ES2755909T3 (es) * 2010-07-12 2020-04-24 Celgene Corp Formas sólidas de la romidepsina y sus usos
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CA2845806C (en) 2011-09-13 2019-06-11 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
EP2915536B1 (en) * 2012-11-01 2019-08-21 Microbial Chemistry Research Foundation Anticancer agent, and combination use anticancer agent
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN116327887B (zh) * 2023-04-24 2023-11-03 南京捷因诊断技术有限公司 一种lsd1抑制剂作为抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486379A (en) * 1892-11-15 Hame-tug
US574455A (en) * 1897-01-05 Switch-lock
US3997633A (en) * 1975-06-24 1976-12-14 Max Leva Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348388A (en) * 1980-04-02 1982-09-07 G.D. Searle & Co. 11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4950755A (en) * 1985-08-12 1990-08-21 Ohio State University Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5514664A (en) * 1990-05-26 1996-05-07 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for application in combatting resistance to drugs
US5620961A (en) * 1994-04-25 1997-04-15 Markovic; Nenad S. Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US6471943B1 (en) * 1996-12-30 2002-10-29 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6286513B1 (en) * 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
AU783504C (en) * 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
KR20020062956A (ko) * 1999-12-08 2002-07-31 싸이트 테라피스 인코포레이티드 면역억제제로서 사용하기 위한 뎁시펩티드 및 이의 동류물
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
PL366100A1 (pl) * 2000-09-22 2005-01-24 Bristol-Myers Squibb Company Sposób zmniejszania toksyczności chemioterapii złożonej
WO2002024178A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
KR20040018341A (ko) * 2001-03-23 2004-03-03 샤이어 바이오켐 인코포레이티드 암치료용 약제 조성물
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
DK1426054T3 (da) * 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
JP4773719B2 (ja) * 2002-05-17 2011-09-14 アベンティス・ファーマ・ソシエテ・アノニム 乳癌および卵巣癌のアジュバント療法におけるドセタキセル／ドキソルビシン／シクロホスファミドの使用
AU2003301251A1 (en) * 2002-10-15 2004-05-04 Ferx Incorporated Magnetically guided particles for radiative therapies
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
BRPI0410648A (pt) 2003-05-21 2006-07-04 Novartis Ag combinação de inibidores de histona desacetilase com agentes quimioterápicos
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7056883B2 (en) * 2003-06-27 2006-06-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US7314862B2 (en) 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
JP4779971B2 (ja) 2011-09-28
EP1670514B1 (en) 2010-06-23
DE602004027824D1 (de) 2010-08-05
DK2263694T3 (da) 2013-08-26
EP1670514A2 (en) 2006-06-21
CY1114359T1 (el) 2016-08-31
WO2005030239A3 (en) 2005-07-28
CA2540108A1 (en) 2005-04-07
PT2263694E (pt) 2013-08-27
PL2263694T3 (pl) 2013-11-29
US20050070467A1 (en) 2005-03-31
US7314862B2 (en) 2008-01-01
WO2005030239A2 (en) 2005-04-07
EP2263694A1 (en) 2010-12-22
ATE471740T1 (de) 2010-07-15
SI2263694T1 (sl) 2013-09-30
ES2344899T3 (es) 2010-09-09
MXPA06003222A (es) 2006-05-22
JP2007506647A (ja) 2007-03-22
ES2425083T3 (es) 2013-10-11
EP2263694B1 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
PL1670514T3 (pl) Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
TW200738725A (en) Unsaturated mTOR inhibitors
TW200801006A (en) Fused bicyclic mTOR inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
TW200626131A (en) C-aryl glucoside SGLT2 inhibitors and method
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
SI1940786T1 (sl) Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C
WO2009156735A3 (en) New therapeutic agents
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2003080582A3 (de) Fredericamycin-derivate
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2002249890A1 (en) Carboline derivatives
MXPA03010761A (es) Combinaciones farmaceuticas.
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
TW200508199A (en) Novel compound
IL174121A0 (en) Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
WO2006055621A3 (en) Histone deacetylase inhibitors and methods of use
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
MX2007002600A (es) Mercaptoamidas como inhibidores de la histona deacetilasa.